FINWIRES · TerminalLIVE
FINWIRES

モルガン・スタンレーは、eBayの下半期の成長鈍化は過大評価されていると指摘

By

-- eBay(EBAY)の2023年下半期における商品総売上高(GMV)成長率の減速が投資家の懸念材料となっているが、モルガン・スタンレーは木曜日のレポートで、市場は継続的な好業績を支える明確な要因を過小評価しており、株価の下落は買いの好機と捉えていると指摘した。 同社は第1四半期に為替変動の影響を除いたGMV成長率が14%となり、ガイダンスの上限を上回った。しかし、同レポートによると、下半期のガイダンスでは、上半期の約12%成長から3%程度へと急減速すると見込まれている。 モルガン・スタンレーは、この乖離こそが議論の焦点であり、eBayは幅広い事業セグメントにおける勢い、eBay Liveや車両販売といった新たな成長分野、これまで一貫して保守的なガイダンスを維持してきた実績、そして人工知能(AI)を活用したツールによる成長の可能性を背景に、下半期も好業績を維持すると予想している。 投資会社は、同社が下半期に中程度の1桁台の商品取扱高成長を達成できるとの確信を強めていると述べ、成長の持続性が明確になるにつれて、さらなる業績予想の上方修正と株価の上昇余地が生まれる可能性が高いと指摘した。 モルガン・スタンレーは同社株の投資判断を「オーバーウェイト」に据え置き、目標株価を117ドルから121ドルに引き上げた。 eBayの株価は木曜日の取引で2.7%下落した。

Price: $101.02, Change: $-2.77, Percent Change: -2.67%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM